Rebamipide

Rebamipide

SCHEMBL29560992

O=C(N[C@H](Cc1cc(=O)[nH]c2ccccc12)C(=O)O)c1ccc(Cl)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
UBASH3B Q8TF42 1/20 1.00
PPARG P37231 1/20 0.55
ITGB2 P05107 6/20 0.55
ICAM1 P05362 6/20 0.55
ITGAL P20701 6/20 0.55
F11 P03951 2/20 0.54
ERAP2 Q6P179 1/20 0.54
TACR1 P25103 2/20 0.52
CCKBR P32239 1/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
CA2 P00918 1/20 0.48
PIN1 Q13526 1/20 0.48
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA9 Q16790 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Rebamipide SCHEMBL21623658 1.00 UBASH3B (1.00) UBASH3BPPARGITGB2ICAM1ITGAL
Rebamipide SCHEMBL23346201 1.00 UBASH3B (1.00) UBASH3BPPARGITGB2ICAM1ITGAL
Rebamipide SCHEMBL221527 1.00 UBASH3B (1.00) UBASH3BPPARGITGB2ICAM1ITGAL
Rebamipide SCHEMBL5794018 1.00 UBASH3B (1.00) UBASH3BPPARGITGB2ICAM1ITGAL
Rebamipide SCHEMBL9114879 0.99 UBASH3B (0.98) UBASH3BPPARGITGB2ICAM1ITGAL
Rebamipide SCHEMBL28798513 0.99 UBASH3B (0.98) UBASH3BPPARGITGB2ICAM1ITGAL
Rebamipide SCHEMBL27819911 0.99 UBASH3B (0.98) UBASH3BPPARGITGB2ICAM1ITGAL
Rebamipide SCHEMBL2292009 0.99 UBASH3B (0.98) UBASH3BPPARGITGB2ICAM1ITGAL
Rebamipide SCHEMBL26607917 0.99 UBASH3B (0.98) UBASH3BPPARGITGB2ICAM1ITGAL
Rebamipide SCHEMBL27858766 0.99 UBASH3B (0.98) UBASH3BPPARGITGB2ICAM1ITGAL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260091018-A1 COMBINATION PREPARATION CONTAINING HETEROCYCLIDENE ACETAMIDE DERIVATIVE SENJU PHARMACEUTICAL CO., LTD. (JP) 2026-04-02 US disclosed
US-12370140-B2 Micelle for solubilizing a sparingly water-soluble ingredient and solution comprising the same TEIKA PHARMACEUTICAL CO., LTD. (JP) 2025-07-29 US disclosed
CN-119997947-A Combination preparation containing heterocyclic subunit acetamide derivative 千寿制药株式会社 2025-05-13 CN disclosed
WO-2024071349-A1 COMBINATION PREPARATION CONTAINING HETEROCYCLIDENE ACETAMIDE DERIVATIVE 千寿製薬株式会社 2024-04-04 WO disclosed
CN-112816585-B Method for detecting rebamipide and related substances thereof 苏州正济药业有限公司 2022-09-27 CN disclosed
US-20220233438-A1 MICELLE FOR SOLUBILIZING A SPARINGLY WATER-SOLUBLE INGREDIENT AND SOLUTION COMPRISING THE SAME TEIKA PHARMACEUTICAL CO., LTD. (JP) 2022-07-28 US disclosed
US-11318095-B2 Micelle for solubilizing a sparingly water-soluble ingredient and solution comprising the same TEIKA PHARMACEUTICAL CO., LTD. (JP) 2022-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11318095-B2 Micelle for solubilizing a sparingly water-soluble ingredient and solution comprising the same CETP, LIPA, MUC1 UBASH3B 2649/4885PPARG 2501/4885ITGB2 4450/4885
US-12370140-B2 Micelle for solubilizing a sparingly water-soluble ingredient and solution comprising the same CETP, LIPA, MUC1 UBASH3B 2649/4885PPARG 2501/4885ITGB2 4450/4885
US-20260091018-A1 COMBINATION PREPARATION CONTAINING HETEROCYCLIDENE ACETAMIDE DERIVATIVE HACD3, LIPA, IL2 UBASH3B 1976/4885PPARG 2023/4885ITGB2 3975/4885
US-20220233438-A1 MICELLE FOR SOLUBILIZING A SPARINGLY WATER-SOLUBLE INGREDIENT AND SOLUTION COMPRISING THE SAME CETP, LIPA, MUC1 UBASH3B 2649/4885PPARG 2501/4885ITGB2 4450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.